Clinical trials: Tumor Immunity
Multiple Myeloma
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune…
- Trial name
- PCV13 (NCT01852591)
- Testing
- PCV 13
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Fasting
Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients
This study will evaluate the ability of short-term fasting to reduce chemotherapy toxicity and enhance anti-tumour response in patients with colorectal carcinoma subjected to chemotherapy.
- Trial name
- CHEMOFAST (NCT04247464)
- Testing
- Fasting
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- IMDEA Food
Hepatocellular Carcinoma, Immune Response
Immunological Response After Ablative Therapy in the Liver
Local ablative treatment of Hepatocellular Carcinoma is performed primary on patients not eligible for liver transplant or liver resection.
- Trial name
- IRAL (NCT03040453)
- Testing
- Microwave ablation, Irreversible electroporation
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Healthy Adult Female Participants, Prevention
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
This study was conducted to assess the safety, immunogenicity, efficacy and long-term effectiveness of a vaccine being evaluated for the prevention of human papillomavirus (HPV) infection and disease in mid-adult women.
- Conditions
- Healthy Adult Female Participants, Prevention, Papillomavirus Infection, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
- Trial name
- NCT00090220
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,819 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer, Breast Cancer
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.
- Conditions
- Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT06246968
- Testing
- Pembrolizumab, Cryoablation, Histotripsy
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Tumor Immunity and Cancer Recurrence Prediction Model
The purpose of this observational study is to understand the predictive effect of the laboratory-developed TIMES scoring system on the recurrence status of cancer patients who have undergone surgical tumor resection.
- Trial name
- NCT06855290
- Volunteers
- 300 people
- Sponsor
- Anhui Provincial Hospital
Cancer, Neoplasm
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
This cancer vaccine research study involves the injection of the NY-ESO-1b peptide along with 2 other agents to help stimulate the immune system. Peptides are small fragments of protein.
- Trial name
- NCT00199836
- Testing
- NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Ludwig Institute for Cancer Research
HIV Infections
A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients
The purpose of this study is to determine if TNFR:Fc (a molecule that attaches to TNF) can lower the amount of IL-6 in HIV-positive patients. This study will also examine the effect of TNFR:Fc on TNF-alpha.
- Trial name
- NCT00001116
- Testing
- Tumor Necrosis Factor soluble receptor-immunoadhesin complex
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous T-cell Lymphoma, Sezary Syndrome
In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.
- Conditions
- Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides
- Trial name
- NCT00177190
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pittsburgh
Multiple Myeloma, Autologous Stem Cell Transplant
Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients
This research study is being done to determine if Distance Reiki therapy offers a quality of life benefit, and improves immunity compared to patients receiving Sham Distance Reiki therapy or no additional Reiki intervention.
- Trial name
- NCT04783038
- Testing
- Distance Reiki
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I clinical trial studies the side effects of sirolimus and NY-ESO-1 protein with MIS416 in treating patients stage II-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Fallopian Tube Cancer
- Trial name
- NCT02833506
- Testing
- Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Myeloma, Lymphoma
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
A prospective study in which hematological oncology patients who were vaccinated against RSV will undergo a blood test to assess their immune response to the vaccine.
- Conditions
- Myeloma, Lymphoma, CLL, Myelodysplastic Syndrome
- Trial name
- NCT06944119
- Where
- Israel
- Volunteers
- 250 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Infections
The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections
The purpose of this study is to better understand genetic susceptibility to infections and the interactions of specific genetic polymorphisms of innate immune receptors with microbial and fungal organisms.
- Trial name
- NCT00597090
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sezary Syndrome
Extracorporeal Photopheresis in Sezary Syndrome
The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months.
- Trial name
- ECP (NCT05157581)
- Testing
- Extracorporeal photopheresis (ECP), Methoxsalen Injection
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Oleg E. Akilov, MD, PhD
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
- Trial name
- NCT06319963
- Testing
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Theravectys S.A.
Epstein Barr Virus (EBV) Infection
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
To evaluate the safety, immune-response and efficacy of GSK Biologicals' EBV vaccine in a population at risk of developing infectious mononucleosis.
- Trial name
- NCT00430534
- Testing
- EBV vaccine (268664)
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Henogen
Recurrent Melanoma, Stage IA Melanoma
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma.
- Conditions
- Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma
- Trial name
- NCT00003895
- Testing
- HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Biochemical Recurrent Prostate Cancer
Radium-223 in Biochemically Recurrent Prostate Cancer
Background: Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prostate cancer.
- Trial name
- NCT04206319
- Testing
- Radium-223, 18F Sodium Fluoride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
BCC - Basal Cell Carcinoma, Immune Response
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas
The study aim is to assess the immunological and clinical response in basal cell carcinoma (BCC) treated with ablative fractionated laser (AFL) as monotherapy and compare with BCC treated with combination-therapy of AFL and the…
- Conditions
- BCC - Basal Cell Carcinoma, Immune Response, Immunotherapy, Ablative Fractionated Laser
- Trial name
- NCT04570683
- Testing
- Nivolumab 10 MG/ML, Ablative fractionated laser
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Bispebjerg Hospital
Indolent Lymphoproliferative Disorders
Low Grade Lymphoma
The purpose of this study is to assess the seroconversion rate and the cellular immune response after vaccination against hepatitis B virus in patients with lymphoproliferative syndrome like chronic lymphocytic leukemia stade A…
- Trial name
- EVACC-B (NCT01698866)
- Testing
- Vaccin GenHevac B Pasteur
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Central Hospital, Nancy, France